CarlCurtisPeckMD

PubMed

• Farewell to our Wonderful Friend and Colleague, J. Richard (Dick) Crout (1929–2020)
  Robert Temple, Robert T. O'Neill, Carl C. Peck> ;Clinical Pharmacology and Therapeutics. 2021 Jun 1
• 7 citations
  Scientific considerations for global drug development.
  Jennifer L. Wilson, Kit Wun Kathy Cheung, Lawrence Lin, Elizabeth A. E. Green, Analía Porrás, Ling Zou, David Mukanga, Paul A. Akpa, Delese Mimi Darko, Rae Yuan, Sheng...> ;Science Translational Medicine. 2020 Jul 29
• Sir Alasdair Breckenridge 1937–2019. A Celebratory Tribute
  Carl C. Peck, Ross A. Breckenridge> ;Clinical Pharmacology and Therapeutics. 2020 Jul 1
• Author Correction: At the end of the beginning: immunotherapies as living drugs.
  Ellen G. Feigal, Natalie DeWitt, Cathy Cantilena, Carl C. Peck, David F. Stroncek> ;Nature Immunology. 2019 Oct 1
• 4 citations
  At the end of the beginning: immunotherapies as living drugs.
  Ellen G. Feigal, Natalie DeWitt, Cathy Cantilena, Carl C. Peck, David F. Stroncek> ;Nature Immunology. 2019 Aug 1
• 18 citations
  Report on the current status of the use of real‐world data (RWD) and real‐world evidence (RWE) in drug development and regulation
  Alasdair Breckenridge, Ross A. Breckenridge, Carl C. Peck> ;British Journal of Clinical Pharmacology. 2019 Jul 10
• 1 citations
  Bayesian Approach to Establish Bioequivalence: Why and How?
  Carl C. Peck, Gregory Campbell> ;Clinical Pharmacology and Therapeutics. 2019 Feb 1
• Farewell to Our Good Friend, Outstanding Mentor, and Colleague Darrell R. Abernethy (1949-2017).
  Janice B. Schwartz, Raymond L. Woosley, Carl C. Peck> ;Clinical Pharmacology and Therapeutics. 2018 Apr 1
• 4 citations
  Individualized treatment strategies for hyperuricemia informed by a semi-mechanistic exposure-response model of uric acid dynamics.
  Sergey Aksenov, Carl C. Peck, Ulf Eriksson, Donald R. Stanski> ;Physiological Reports. 2018 Mar 1
• 48 citations
  Poor medication adherence in clinical trials: consequences and solutions
  Alasdair Breckenridge, Jeffrey K Aronson, Terrence F. Blaschke, Dan Hartman, Carl C. Peck, Bernard Vrijens> ;Nature Reviews. Drug Discovery. 2017 Mar 1
• 19 citations
  Determination of the starting dose in the first-in-human clinical trials with monoclonal antibodies: a systematic review of papers published between 1990 and 2013.
  Hoon Young Suh, Carl C. Peck, Kyung Sang Yu, Howard Lee> ;Drug Design, Development and Therapy. 2016 Dec 8
• 1 citations
  Farewell to our Good Friend and Outstanding Colleague David Flockhart (1952-2015).
  Carl C. Peck, Raymond L. Woosley> ;Clinical Pharmacology and Therapeutics. 2016 Feb 1
• 19 citations
  17α-Ethynylestradiol-3-sulfate treatment of severe blood loss in rats.
  William J. Hubbard, James Keith, Judith Berman, Matthew W. Miller, Charles M. Scott, Carl C. Peck, Irshad H. Chaudry> ;The Journal of Surgical Research. 2015 Jan 1
• 20 citations
  Efficacy of 17α-ethynylestradiol-3-sulfate for severe hemorrhage in minipigs in the absence of fluid resuscitation.
  Matthew Miller, James Keith, Judith Berman, D. Bruce Burlington, Charles Grudzinskas, William J. Hubbard, Carl C. Peck, Charles M. Scott, Irshad H. Chaudry> ;The Journal of Trauma and Acute Care Surgery. 2014 Jun 1
• 16 citations
  Impact of the Pharmaceutical Sciences on Health Care: A Reflection over the Past 50 Years
  Malcolm Rowland, Christian R. Noe, Dennis A. Smith, Geoffrey T. Tucker, Daan J.A. Crommelin, Carl C. Peck, Mario L. Rocci, Luc Besançon, Vinod P. Shah> ;Journal of Pharmaceutical Sciences. 2012 Nov 1
• 416 citations
  Physiologically-based pharmacokinetics in drug development and regulatory science.
  Malcolm Rowland, Carl C. Peck, Geoffrey Tucker> ;Annual Review of Pharmacology and Toxicology. 2011 Jan 6
• 15 citations
  Quantitative clinical pharmacology is transforming drug regulation.
  Carl C. Peck> ;Journal of Pharmacokinetics and Pharmacodynamics. 2010 Oct 27
• 53 citations
  A roadmap for biomarker qualification
  David G. Warnock, Carl C. Peck> ;Nature Biotechnology. 2010 May 1
• 31 citations
  Recommended changes to oncology clinical trial design: revolution or evolution?
  Mark J. Ratain, R. Humphrey, Gary Gordon, Gwen Fyfe, Peter C. Adamson, Thomas R. Fleming, Walter M. Stadler, Donald A. Berry, Carl C. Peck> ;European Journal of Cancer. 2008 Jan 1
• 23 citations
  “Getting the Dose Right”: Facts, a Blueprint, and Encouragements
  Carl C. Peck, J T Cross> ;Clinical Pharmacology and Therapeutics. 2007 Jul 1
• 6 citations
  Current issues relating to drug safety especially with regard to the use of biomarkers: a meeting report and progress update.
  Paul Rolan, Meindert Danhof, Donald R. Stanski, Carl C. Peck> ;European Journal of Pharmaceutical Sciences. 2007 Feb 1
• 24 citations
  Simulation of correlated continuous and categorical variables using a single multivariate distribution.
  Stacey Tannenbaum, Nicholas H. G. Holford, Howard Lee, Carl C. Peck, Diane R. Mould> ;Journal of Pharmacokinetics and Pharmacodynamics. 2006 Oct 12
• 14 citations
  Evidence of effectiveness: How much can we extrapolate from existing studies?
  Howard Lee, Dong-Seok Yim, Honghui Zhou, Carl C. Peck> ;The AAPS Journal. 2005 Oct 5
• 61 citations
  Population pharmacokinetic analysis and simulation of the time-concentration profile of etanercept in pediatric patients with juvenile rheumatoid arthritis.
  Dong-Seok Yim, Honghui Zhou, Mary Buckwalter, Ivan Nestorov, Carl C. Peck, Howard Lee> ;Journal of Clinical Pharmacology. 2005 Mar 1
• 21 citations
  Randomized concentration-controlled trials: Motivations, use, and limitations
  Holger Kraiczi, Theo Jang, Thomas M. Ludden, Carl C. Peck> ;Clinical Pharmacology and Therapeutics. 2003 Sep 1
• Join now to see all